Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

GermanyBack to Germany

Clinical trials in Duesseldorf – page 21

405 clinical trials in Duesseldorf, Germany across 5 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Duesseldorf at a glance
405
clinical trials
  • Research sites5
Type of trial
Recruitment status
Quick filters

405 trials in Duesseldorf

Open in trial search

Neovascular age-related macular degeneration

Not recruiting

A study comparing 4D-150 and aflibercept for adults with abnormal blood vessel growth in the eye due to age-related macular degeneration

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:4d Molecular Therapeutics Inc.

Immune thrombocytopenia

Not recruiting

A Study of Ianalumab and Eltrombopag for Patients with Primary Immune Thrombocytopenia Who Did Not Respond Well to or Relapsed After Steroid Treatment

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Eltrombopag
  • Sponsor:Novartis Pharma AG

Chronic kidney disease+1

Not recruiting

A study of ziltivekimab compared to placebo in people with heart and blood vessel disease, chronic kidney disease and inflammation

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ziltivekimab
  • Sponsor:Novo Nordisk A/S

PIK3CA related overgrowth spectrum

Not recruiting

Study of alpelisib in children and adults with PIK3CA-Related Overgrowth Spectrum (PROS)

Investigational
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Alpelisib
  • Sponsor:Novartis Pharma AG

Hormone-dependent prostate cancer

Not recruiting

Study of luxdegalutamide and abiraterone combination in adult men with metastatic hormone-sensitive prostate cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone
  • Sponsor:Novartis Pharma AG

Neoplasm malignant

Not recruiting

Study of S095035 and TNG462 in adults with advanced or metastatic solid tumors with MTAP deletion

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:S095035
  • Sponsor:Institut De Recherches Internationales Servier IRIS

Primary hyperaldosteronism

Not recruiting

Study of baxdrostat compared to placebo to treat adults with primary aldosteronism

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Baxdrostat
  • Sponsor:AstraZeneca AB

Colorectal cancer

Not recruiting

A study of futibatinib combined with tislelizumab, fluorouracil, calcium folinate, and oxaliplatin as first-line treatment for patients with colorectal cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Fluorouracil
  • Sponsor:Institut fuer Klinische Krebsforschung IKF GmbH

Pneumococcal immunisation

Not recruiting

Study on the Safety and Immune Response of a 21-Valent Pneumococcal Conjugate Vaccine in Healthy Infants and Toddlers

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · Healthy volunteers
  • Substances:Pneumococcal Polysaccharide Serotype 1
  • Sponsor:Sanofi Vaccines US Inc.

Dermatitis atopic

Not recruiting

Study on Preventing Atopic Dermatitis in High-Risk Children Using Paraffin White Soft Cream

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · Healthy volunteers
  • Substances:Paraffin White Soft
  • Sponsor:INFECTOPHARM Arzneimittel und Consilium GmbH

Inclusion body myositis

Not recruiting

Title: Long-term safety and effectiveness study of Ulviprubart in patients with inclusion body myositis who completed previous treatment

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:ULVIPRUBART
  • Sponsor:Abcuro Inc.

VEXAS syndrome

Not recruiting

Study of pacritinib effectiveness and safety compared to placebo in patients with VEXAS syndrome

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Pacritinib
  • Sponsor:Sobi Inc.

Other cities in Germany

The busiest research cities in the country

All 516 cities in Germany

Clinical research in Duesseldorf

What the registry says about research in the country

01 Oncology Research

Innovative trials focusing on colorectal cancer, breast cancer, and esophageal cancer treatments. Studies evaluate novel combination therapies and targeted treatments for various cancer types.

  • Metastatic Colorectal Cancer Treatment
  • HER2-positive Breast Cancer Therapy
  • Advanced Bladder Cancer Management

Research includes promising immunotherapy combinations and specialized treatments for different cancer stages.

02 Dermatological Studies

Comprehensive research on atopic dermatitis, pyoderma gangrenosum, and plaque psoriasis. Studies focus on preventive measures and innovative treatments for chronic skin conditions.

  • Pediatric Dermatitis Prevention
  • Inflammatory Skin Conditions
  • Advanced Psoriasis Therapeutics

Emphasis on both preventive care and treatment of severe skin manifestations.

03 Autoimmune and Inflammatory Disorders

Studies examining treatments for multiple sclerosis, uveitis, and graft-versus-host disease. Research aims to develop targeted therapies for complex autoimmune conditions.

  • MS Treatment Innovations
  • Inflammatory Eye Conditions
  • Transplant-Related Complications

Focus on improving patient outcomes through novel therapeutic approaches.

Back to GermanyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.